About Ionis
Ionis is a publicly listed company based in United States founded in 1989. RNA-targeted medicines are developed for various diseases. The company has 1,070 employees. Its chief executive, as recorded, is Brett P Monia. Its website ionis.com draws about 54 thousand monthly visits. Ionis offers products and services including RNA-targeted Medicines. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is IONIS PHARMACEUTICALS, INC. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Ionis was founded in 1989 in the United States and operates in the biotechnology sector. Genetic medicines, with a focus on RNA-targeted therapeutics, are developed to target the root causes of diseases. Operations center on research and development of treatments for a range of conditions, including rare and neurological disorders. The company is headquartered in Carlsbad, California, and maintains a global presence through partnerships and clinical trials.
- Annual Revenue$943.71 M (USD)33.83as on Dec 31, 2025
- Net Profit-$381.39 M (USD)15.97as on Dec 31, 2025
- EBITDA-$358.99 M (USD)20.77as on Dec 31, 2025
- Latest Funding Round$924.03K (USD), Grant
Aug 2009
- InvestorsHHS
& 1 more
- Employee Count1,070
Products & Services of Ionis
Ionis offers a comprehensive portfolio of products and services, including RNA-targeted Medicines.
Treats serious diseases by targeting RNA molecules
Funding Insights of Ionis
- Total Rounds 9
- Last Round Grant — $924,028
- First Round $744,910
(Apr 2004)
- Investors Count 2
All 9 funding rounds of Ionis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Ionis
Ionis has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Ojp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Federal justice system funding, training, and resources are provided. | ojp.gov |
Investor details for Ionis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ionis
319 people are tracked at Ionis (227 in leadership, 10 in board & advisors, 82 in team); the tracked headcount is 1,070.
| Name | Role | Group |
|---|---|---|
Brett P Monia | CEO | Leadership |
Sanjay Bhanot | Vice President Metabolics & Translational Medicine | Leadership |
C. Frank Bennett | EVP, Chief Scientific Officer | Leadership |
Kevin Cornetto | Director, Drug Safety Surveillance | Leadership |
Samuel Abariga | Medical Director, Drug Safety & Pharmacovigilance | Leadership |
Isaac Ballesteros | Assistant Director, Accounting | Leadership |
Ewa Karwatowska-Prokopczuk | VP, Cardiovascular Medicine | Leadership |
Patrick R. O’Neil | Chief Legal Officer and General Counsel | Leadership |
Alex Behling | Assistant Director- Biomarkers Bioanalysis | Leadership |
Adam Mullick | VP, Drug Discovery | Leadership |
Leo Sahelijo | VP, Translational Medicine | Leadership |
John Su | VP, Biometrics | Leadership |
Shannon Devers | Executive Vice President, Chief Human Resources Officer | Leadership |
Daniel Capaldi | VP, Analytical & Process Chemistry | Leadership |
Eric Swayze | Executive Vice President, Research At Ionis Pharmaceuticals, Inc. | Leadership |
Isaiah Cedillo | Executive Director, Manufacturing & Operations | Leadership |
Pratap Singh | Executive Director, Clinical Pharmacology | Leadership |
Holly Kordasiewicz | VP, Drug Discovery | Leadership |
Eugene Schneider | Executive Vice President, Chief Clinical Development Officer | Leadership |
Richard S. Geary | EVP, Chief Development Officer | Leadership |
299 more people are available in the full profile.
Complete people profiles for Ionis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ionis
Ionis is a publicly listed company on the NASDAQ with ticker symbol IONS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jul 2017
- Listed onNASDAQ: AKCA
- Listed entityIonis Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS4622221004
- Share price$42.38 (-2.95% on the day) · 2026-10-13
- Market capitalisation$7.04B
- EPS (diluted, trailing year)$-3.47
- Volume (last session)2,978,032
Financials of Ionis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $943.7M | -$381.4M | -$359.0M |
| 2024 | $705.1M | -$453.9M | -$453.1M |
| 2023 | $787.6M | -$366.3M | -$331.2M |
| 2022 | $587.4M | -$269.7M | -$388.1M |
| 2021 | $810.5M | -$28.6M | -$10.6M |
Detailed financial statements for Ionis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Ionis
4 dated milestones of Ionis across 28 years, from founding to its latest funding, stage changes and deals.
- Founded Ionis is founded.
- Funding First funding round of $745K.
- Funding Latest funding round, Grant, of $924K.
- IPO Lists on the stock exchange (IPO).
Competitors of Ionis
Ionis has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Ionis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ionis
The website of Ionis (ionis.com) receives about 54.3K visits a month and ranks #738,122 among all websites worldwide, #848 in Biotechnology and Pharmaceuticals.
- Monthly visits54.3K
▲ 17.6% vs previous month
- Unique visitors21.6K
per month
- Global rank#738,122
among all websites
- Category rank#848
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.7
- Average visit37 sec
- DevicesDesktop 37% · Mobile 63%
Websites whose visitors overlap most with Ionis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| theratech.com | 100% | 5.5K | #5,174,204 | View details | |
| pharmashots.com | 99% | #2,147,167 | View details | ||
| argonautms.com | 98% | 9.6K | #2,712,987 | View details | |
pipelinereview.com | pipelinereview.com | 96% | – | ||
| bioratherapeutics.com | 95% | 1.8K | #6,912,037 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Ionis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Ionis (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ionis
Complete news archive for Ionis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ionis
Ionis was founded in 1989 and raised its 1st funding round 15 years after it was founded.
Ionis is headquartered in United States.
Brett P Monia is the CEO of Ionis, as recorded in our data.
Ionis has 1,070 employees.
Annual revenue of Ionis is $943.71M as on Dec 31, 2025.
Ionis was founded in 1989 in the United States and operates in the biotechnology sector. Genetic medicines, with a focus on RNA-targeted therapeutics, are developed to target the root causes of diseases. Operations center on research and development of treatments for a range of conditions, including rare and neurological disorders. The company is headquartered in Carlsbad, California, and maintains a global presence through partnerships and clinical trials.
Ionis's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Ionis offers RNA-targeted Medicines.
Yes, Ionis is publicly traded on NASDAQ under the ticker symbol IONS.
Ionis operates through Ionis Pharmaceuticals, Inc..